Related references
Note: Only part of the references are listed.Association of thiazolidinedione with a lower risk of Parkinson's disease in a population with newly-diagnosed diabetes mellitus
Hsiu-Li Lin et al.
ANNALS OF MEDICINE (2018)
Association between diabetes and subsequent Parkinson disease A record-linkage cohort study
Eduardo De Pablo-Fernandez et al.
NEUROLOGY (2018)
Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan
Hsiu-Feng Wu et al.
BMJ OPEN (2018)
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
Seyed Soheil Saeedi Saravi et al.
METABOLIC BRAIN DISEASE (2017)
Glitazone Use Associated With Reduced Risk of Parkinson's Disease
Brage Brakedal et al.
MOVEMENT DISORDERS (2017)
PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Juan M. Zolezzi et al.
BIOLOGICAL REVIEWS (2017)
Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders
Swati Agarwal et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Statin Therapy Prevents the Onset of Parkinson Disease in Patients with Diabetes
Kun-Der Lin et al.
ANNALS OF NEUROLOGY (2016)
The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis
Lauren Hirsch et al.
NEUROEPIDEMIOLOGY (2016)
Monte Carlo cross-validation analysis screens pathway cross-talk associated with Parkinson's disease
Tianrong Li et al.
NEUROLOGICAL SCIENCES (2016)
Thiazolidinediones and Parkinson Disease: A Cohort Study
John G. Connolly et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study
Ruth Brauer et al.
PLOS MEDICINE (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Diabetes and Risk of Parkinson's Disease A systematic review and meta-analysis
Emanuele Cereda et al.
DIABETES CARE (2011)
Diabetes and the Risk of Developing Parkinson's Disease in Denmark
Eva Schernhammer et al.
DIABETES CARE (2011)
PPAR: a therapeutic target in Parkinson's disease
Rajnish K. Chaturvedi et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist
Nektaria Nicolakakis et al.
JOURNAL OF NEUROSCIENCE (2008)
Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity
Bin Xing et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Burden of comorbid medical conditions and quality of diabetes care
Jewell H. Halanych et al.
DIABETES CARE (2007)
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation
T Dehmer et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
T Breidert et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Share Paper
